Wall Street analysts forecast that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will announce sales of $21.26 million for the current quarter, Zacks reports. Five analysts have issued estimates for Alnylam Pharmaceuticals’ earnings. The lowest sales estimate is $13.13 million and the highest is $37.00 million. Alnylam Pharmaceuticals reported sales of $8.71 million during the same quarter last year, which indicates a positive year-over-year growth rate of 144.1%. The firm is scheduled to announce its next quarterly earnings report on Thursday, August 3rd.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year sales of $21.26 million for the current fiscal year, with estimates ranging from $25.00 million to $104.96 million. For the next fiscal year, analysts forecast that the firm will post sales of $113.37 million per share, with estimates ranging from $78.56 million to $191.07 million. Zacks’ sales averages are an average based on a survey of research firms that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.22) by $0.03. Alnylam Pharmaceuticals had a negative net margin of 705.11% and a negative return on equity of 42.90%. The business had revenue of $19 million during the quarter, compared to analysts’ expectations of $22.91 million. During the same period last year, the company posted ($1.21) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 160.3% on a year-over-year basis.

A number of research firms recently weighed in on ALNY. BidaskClub raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 13th. ValuEngine raised shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Chardan Capital set a $110.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Monday, June 12th. Janney Montgomery Scott began coverage on shares of Alnylam Pharmaceuticals in a report on Friday, June 2nd. They issued a “sell” rating and a $67.00 target price for the company. Finally, Piper Jaffray Companies set a $116.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, May 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $71.29.

In related news, VP Michael Mason sold 9,375 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $70.00, for a total value of $656,250.00. Following the completion of the sale, the vice president now directly owns 5,625 shares in the company, valued at $393,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sanofi acquired 297,501 shares of the firm’s stock in a transaction that occurred on Wednesday, May 31st. The stock was purchased at an average price of $71.87 per share, with a total value of $21,381,396.87. The disclosure for this purchase can be found here. Insiders have sold 64,125 shares of company stock valued at $4,325,000 over the last three months. Insiders own 4.30% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. First Manhattan Co. purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at $135,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at $148,000. Westpac Banking Corp purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at $202,000. Prudential Financial Inc. purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at $215,000. Finally, Nisa Investment Advisors LLC purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at $256,000. Hedge funds and other institutional investors own 90.04% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Quarterly Sales of $21.26 Million” was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/06/21/analysts-expect-alnylam-pharmaceuticals-inc-alny-will-post-quarterly-sales-of-21-26-million.html.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 81.63 on Wednesday. The stock has a 50 day moving average of $67.47 and a 200-day moving average of $51.64. The stock’s market cap is $7.04 billion. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $84.18.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.